VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF TRD208 “NON-OPIOID MULTI-TARGET MULTI-MODAL ANALGESIC”

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2025

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON LM-350 "CDH17 ADC" APPROVED BY THE NMPA

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2025

VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER WAS PRESENTED AT ESMO 2025

VOLUNTARY ANNOUNCEMENT - INCLUSION OF TQ-B3234 “SELECTIVE MEK1/2 INHIBITOR” IN THE BREAKTHROUGH THERAPY DESIGNATION PROCESS

VOLUNTARY ANNOUNCEMENT - TQB2102 "HER2 BISPECIFIC ADC" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2025